The present invention is directed to a pharmaceutical composition containing a cancer-treating effective amount of a class of prostacyclin derivatives, and a pharmaceutically acceptable carrier, and to kits and methods of employing the same for the treatment of cancer. Monitoring and control of the laser sub-modules within the architecture may be performed to achieve desired performance metrics. Upon detecting the CRC, the receiving STA can terminate reception of the frame early to conserve power, and then enter a low power operational mode to further conserve power.